Endometriosis Treatment Market 2021 Growth, Key Regions, Segments, Worldwide Players and Pharmaceutical Sector to Inspire Better Intake of Global Market

SEATTLE, April 09, 2021, (PHARMIWEB) — Endometriosis is a painful medical condition, in which the tissue lining the inner part of the uterus such as endometrium grows outside the uterus. Endometriosis tissue is found in fallopian tubes, ovaries, and tissue lining the pelvis.

In endometriosis, endometrial tissue that is displaced functions in the usual way such as it thickens, breaks down, and eventually bleeds in every menstrual cycle. Moreover, the displaced tissue has no other way to exit the body, hence, it gets trapped outside the uterus. Involvement of ovaries in endometriosis leads to formation of cysts called endometriomas. Due to this the surrounding tissues form an adhesion (abnormal bands of fibrous tissue that cause pelvic organs and tissues to stick to each other) or a scar tissue near the ovaries.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1999

Primary symptom of endometriosis include pain in pelvic area, which is associated with menstrual cycle. Other signs and symptoms of endometriosis include pain in pelvic region before menstrual cycle, pain in lower back during menstrual period, pain after intercourse in pelvic area, pain during urination, excessive bleeding between periods, fatigue, diarrhea, constipation, and nausea during menstrual cycle. Risk factors of endometriosis include infertility, onset of menstrual cycle at early age, short menstrual cycles, menopause at older age, low body mass index, uterine abnormalities, and medical condition, which prevents normal passage of menstrual flow.

Endometriosis Treatment Market Drivers:-

Increasing research activities for development of new drugs by key players in the global endometriosis treatment market is expected to be a major driver for growth of the market over the forecast period. For instance in 2017, AbbVie, biopharmaceutical company in co-operation with Neurocrine Biosciences Inc submitted a new drug application (NDA) to the U.S. Food and drug Administration (FDA) for a new drug named elagolix. It is an orally administered gonadotropin releasing hormone antagonist, which was evaluated for management of pain associated with endometriosis.

Launch of products by manufacturer is also expected to drive global endometriosis treatment market growth. For instance, in 2018, LASCO distributors in association with Bayer healthcare launched new drug visanne, which is indicated for endometriosis treatment.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1999

Other factors such as increase in prevalence of endometriosis, robust pipeline, awareness about endometriosis are expected to drive endometriosis treatment market growth. For instance, Triptoreline sponsored by University Hospital, Rouen is in Phase 3 Clinical Trials; Triptoreline cures deep endometriosis in the rectum , Myovant Sciences has Relugolix in phase 3 Clinical Trials; Relugolix ceases non-menstrual pelvic pain, Indocyannine Green sponsored by University Hospital in Phase 4 Clinical Trials; Indocyannine Green treats recto vaginal endometriosis, Dienogest sponsored by the University Of Hong Kong is in Phase 4 Clinical Trials; dienogest stops the reoccurance of endometriosis cyst, Merional sponsored by Cario University is in phase 3 Clinical Trials; Merional controls intrauterine insemination cycles in women having endometriosis.

According to a survey conducted by the National Center for Biotechnology Information (NCBI), 2014, endometriosis is estimated to affect 10% of female in the reproductive age and more than 50% in infertility patients, which in turn is expected to fuel growth of the endometriosis treatment market over the forecast period.

Availability of alternative treatment options such as intrauterine systems (IUS) is a key factor that is expected to hamper growth of the market. IUS is a T-shaped device inserted in womb by the doctor. Moreover, treatment of endometriosis include usage of oral contraceptives or GnRH agonists. Most of these therapies have adverse effects on the body due to hormonal changes and it also includes the risk of recurrence of endometriosis.

Endometriosis Treatment Market Regional Analysis:-

Asia Pacific endometriosis treatment market is expected to witness significant growth over the forecast period due to initiative taken by the government to improve health of women in Australia. For instance, according to the George institute of global health, in 2018, Government of Australia allocated around US$ 2.5 million for research in the field of endometriosis. It includes around US$ 120,000 for campaigns, which will provide education and awareness regarding endometriosis and also a research grant for National Health and Medical Research Council.

Europe expected to witness growth in the endometriosis market over the forecast period due to robust drugs pipeline. For instance, Pleyris sponsored by University Magna Graecia is in Phase 3. According to a study conducted by BJOC: An International Journal of Obstetrics and Gynaecology, 2015, in Europe endometriosis affects more than 10% of premenopausal women and 30-50% of the women suffering from symptoms of endometriosis. Increasing number of endometriosis patients is fueling Europe endometriosis treatment market growth.

Endometriosis Treatment Market Key Players:-

Key players operating in global endometriosis treatment market include Astra Zeneca Plc., Eli Lilly and Company, AStellas Pharma, Bayer AG, Meditrina Pharmaceuticals, Abbvie, PfizerInc, Takeda Pharmaceutica, and Neurocrine Biosciences Inc.

Endometriosis Treatment Market Taxonomy:-

By Drug Type

• Oral Contraceptive pills
• Progestin
• Gonadotropin releasing hormone
• Aromatase inhibitors
• Danazol
• Others

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

 By Region

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837